A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen with Open-label Continuation in Cancers that Overexpress th
|Effective start/end date||1/30/06 → 12/31/10|
- CELMED BIOSCIENCES, INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.